natgillin/translations-raw huggingface dataset:
A clinical response to anakinra generally appeared within 2 weeks of initiation of treatment and was sustained with continued administration of anakinra.
Klinični odziv na anakinro se je običajno pojavil v 2 tednih po uvedbi zdravljenja in se je s stalnim dajanjem anakinre vzdrževal.
In RA, CAPS and in Still's disease, your body produces too much of a cytokine called interleukin-1.
Pri RA, CAPS in Stillovi bolezni vaše telo izdeluje preveč citokina, imenovanega interlevkin-1.
For a more comfortable injection, leave at room temperature for approximately 30 minutes or hold the pre-filled syringe gently in your hand for a few minutes.
Da injiciranje ne bo neprijetno, pustite napolnjeno injekcijsko brizgo približno 30 minut na sobni temperaturi ali jo previdno nekaj minut držite v roki.
Hearing and visual acuity did not deteriorate further during anakinra treatment.
Ostrina sluha in vida se ni poslabšala ob nadaljnjem zdravljenju z anakinro.
(Your doctor will have told you what dose you need to use.)
kateri odmerek morate uporabljati.)
Symptoms of lung disease can be e.g. shortness of breath during light exercise, morning cough, and difficulties breathing.
Simptomi pljučne bolezni so lahko npr. oteženo dihanje med lažjo vadbo, jutranji kašelj in težave z dihanjem.
You can now use the pre-filled syringe as described in the “Where should you give your injection?” section and “How do you give your injection?” section.
Zdaj lahko uporabite napolnjeno injekcijsko brizgo, kot je opisano v poglavjih „Kam naj si daste injekcijo?“ in „Kako si daste injekcijo?“ Kam naj si daste injekcijo?
Kineret must be injected under your skin (subcutaneous) daily.
Zdravilo Kineret je treba vsak dan injicirati pod kožo (subkutano).
Inject the liquid slowly and evenly, always keeping the skin pinched as in Figure E.
Tekočino injicirajte počasi in enakomerno; kožo medtem držite med prstoma, kot je prikazano na sliki E.
Contents of the pack and other information What Kineret contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Kineret
The absolute bioavailability of anakinra after a 70 mg subcutaneous bolus injection in healthy subjects (n = 11) is 95%.
Absolutna biološka uporabnost anakinre po subkutani bolusni injekciji 70 mg pri zdravih osebah (n = 11) je 95 %.
• Contact details of their physician
• kontaktne podatke njegovega zdravnika,
* Human interleukin-1 receptor antagonist (r-metHuIL-1ra) produced in Escherichia coli cells by recombinant DNA technology.
* Antagonist humanega receptorja za interlevkin-1 (r-metHuIL-1ra), ki ga izdelujejo v celicah Escherichie coli s tehnologijo rekombinantne DNA.
After injecting the liquid, remove the needle and let go of the skin.
Ko ste tekočino vbrizgali, iglo izvlecite in spustite kožo.
Place a sterile gauze or tissue on a flat surface and hold the syringe above it with the needle pointing towards the gauze or tissue, as shown in Figure C. Make sure the needle does not touch the gauze or tissue.
Položite sterilno gazo ali robček na ravno površino in držite brizgo nad njo tako, da je igla usmerjena proti gazi ali robčku, kot je prikazano na sliki C. Pazite, da se z iglo ne boste dotaknili gaze ali robčka.
Any unused medicine must be discarded.
Neuporabljeno zdravilo je treba zavreči.
• If your doctor has prescribed a lower dose you should continue to the “How to prepare a 20 to 90 mg dose” section.
• Če vam je zdravnik predpisal manjši odmerek, preberite poglavje „Kako pripraviti odmerek od 20 do 90 mg“.
In clinical studies and during post-marketing use, rare cases of opportunistic infections have been observed and have included fungal, mycobacterial, bacterial, and viral pathogens.
V kliničnih študijah in med uporabo po začetku trženja so zabeležili redke primere oportunističnih okužb, ki so vključevale glivične, mikobakterijske, bakterijske in virusne patogene.
Pharmacokinetic data in children < 4 years are lacking, but clinical experience is available from 8 months of age, and when started at the recommended daily dose of 1-2 mg/kg, no safety concerns have been identified.
Podatki o farmakokinetiki pri otrocih do 4 let manjkajo, vendar so na voljo klinične izkušnje od starosti 8 mesecev dalje in ob začetku zdravljenja s priporočenim dnevnim odmerkom 1-2 mg/kg ni bilo pomislekov glede varnosti.
A rapid and sustained decrease in the levels of the inflammatory biomarkers; serum amyloid A (SAA), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and a normalization of inflammatory hematological changes are seen.
Opaziti je hitro in trajajoče zmanjšanje ravni bioloških označevalcev vnetja, serumskega amiloida A (SAA), C-reaktivnega proteina (CRP) in sedimentacije eritrocitov (ESR) ter normalizacijo hematoloških sprememb vnetja.
Population pharmacokinetic analysis demonstrated that the mean plasma clearance value after subcutaneous bolus administration was approximately 14% higher in men than in women and approximately 10% higher in subjects < 65 years than in subjects ≥ 65 years.
Populacijska farmakokinetična analiza je pokazala, da je bila povprečna vrednost plazemskega očistka po subkutani aplikaciji bolusa približno 14 % večja pri moških kot pri ženskah in približno 10 % večja pri osebah, mlajših od 65 let, kot pri osebah, starih 65 let ali več.
The physician educational material should contain:
Izobraževalno gradivo za zdravnika mora vsebovati:
• Instructions on correct injection procedures and disposal of used syringes
• navodila za pravilne postopke injiciranja in odstranjevanja uporabljenih brizg,
Untreated CAPS patients are characterized by increased CRP, SAA and IL-6 relative to normal serum levels.
Za nezdravljene bolniki s CAPS so značilne povečane ravni CRP, SAA in IL-6 glede na normalne ravni seruma.
This treatment combination has not demonstrated increased clinical benefit.
Ta kombinacija zdravil se ni izkazala za klinično koristnejšo.
These data support that no dose adjustment is required for patients with hepatic dysfunction of Child-Pugh Class B. See section 4.2.
Ti podatki potrjujejo, da ni potrebna prilagoditev odmerka za bolnike z jetrno disfunkcijo razreda Child-Pugh B. Glejte poglavje 4.2.
With careful monitoring, Kineret treatment can be continued also during a serious infection.
Pod skrbnim spremljanjem se lahko zdravljenje z zdravilom Kineret nadaljuje tudi med resno okužbo.
Hypersensitivity to the active substance or to to any of the excipients listed in section 6.1 or to E. coli derived proteins.
Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1 ali za beljakovine, ki izvirajo iz E. coli.
Patients with Still's disease have an increased risk of spontaneous development of MAS.
Bolniki s Stillovo boleznijo imajo povišano tveganje za spontani razvoj MAS.
The ejected liquid will be absorbed by the gauze or tissue as shown in Figure C.
Izbrizgana tekočina se bo vpila v gazo ali robček, kot je prikazano na sliki C.
Glucocorticoid doses can in many cases be reduced after initiation of Kineret therapy.
Odmerke glukokortikoidov je možno po začetku zdravljenja z zdravilom Kineret zmanjšati v veliko primerih.
Clinical efficacy and safety in RA
Klinična učinkovitost in varnost pri RA
A subset of these patients continued open-label treatment with Kineret for up to 1 year in a companion extension study.
Podskupina teh bolnikov je nadaljevala odprto zdravljenje z zdravilom Kineret še do enega leta v spremljevalni podaljšani študiji.
If Kineret treatment is continued during serious infections to reduce the risk for a disease flare, careful monitoring is required.
V primeru nadaljevanja zdravljenja z zdravilom Kineret med hudimi okužbami, z namenom zmanjšanja nevarnosti za zagon bolezni, je potrebno skrbno spremljanje.
• The importance of providing patients and/or caregivers with the educational material
• pomembnost zagotavljanja izobraževalnega gradiva bolnikom in/ali skrbnikom.
In general the pharmacokinetics in CAPS patients is similar to that in RA patients.
V splošnem je farmakokinetika pri bolnikih s CAPS podobna kot pri bolnikih z RA.
In a published prospective, uncontrolled, observational cohort study of 20 patients with new-onset SJIA Kineret was used as initial therapy after failure to respond to NSAIDs, but before the use of DMARDs, systemic glucocorticoids, or other biologic agents.
V objavljeni prospektivni, nenadzorovani, opazovalni kohortni študiji z 20 bolniki z novim pojavom SJIA, je bilo zdravilo Kineret uporabljeno kot začetna terapija po neuspešnem odzivu na NSAID, toda pred uporabo DMARD, sistemskih glukokortikoidov ali drugih bioloških učinkovin.
• Never put the pre-filled syringes that you have used into your normal household rubbish bin.
• Uporabljenih napolnjenih injekcijskih brizg ne smete nikdar odvreči med običajne gospodinjske odpadke.
Anakinra had no observed effect on the fertility, early development, embryo-foetal development, or peri- and postnatal development in the rat at doses up to 100 times the human dose (2 mg/kg/day).
Pri anakinri niso opazili učinkov na plodnost, zgodnji razvoj, razvoj zarodka in plodu ali perinatalni in postnatalni razvoj pri podgani v odmerkih, do 100-krat večjih od človeškega odmerka (2 mg/kg/dan).
The influence of demographic covariates on the pharmacokinetics of anakinra was studied using population pharmacokinetic analysis encompassing 341 patients receiving daily subcutaneous injection of anakinra at doses of 30, 75, and 150 mg for up to 24 weeks.
Vpliv demografskih sospremenljivk na farmakokinetiko anakinre so proučevali s populacijsko farmakokinetično analizo, ki je zajela 341 bolnikov, ki so prejemali vsakodnevne subkutane injekcije anakinre v odmerkih po 30, 75 in 150 mg do 24 tednov.
- Serious allergic reactions are uncommon.
- Resne alergijske reakcije se pojavijo občasno.
In clinical trials, interactions between Kineret and other medicinal products (including nonsteroidal anti-inflammatory medicinal products, glucocorticoids, and DMARDs) have not been observed.
V kliničnih preskušanjih niso opazili interakcij med zdravilom Kineret in drugimi zdravili (vključno z nesteroidnimi protivnetnimi zdravili, glukokortikoidi in DMARD).
In the severe form of CAPS, long-term treatment improves the systemic inflammatory organ manifestations of the eye, inner ear, and CNS.
Pri resni obliki CAPS dolgotrajno zdravljenje izboljša pojav znakov vnetja organskih sistemov oči, notranjega ušesa in CŽS.
Infections have been noted in all organ systems and have been reported in patients receiving Kineret alone or in combination with immunosuppressive agents.
Okužbe so opažali na vseh organskih sistemih ter so bile opisane pri bolnikih, ki so dobivali zdravilo Kineret samo ali v kombinaciji z imunosupresivnimi zdravili.
• Physician educational material
• izobraževalno gradivo za zdravnika,
You should position the syringe in one hand with the needle pointing straight upwards as shown in Figure B. Put your thumb on the plunger rod and push slowly until you see a tiny liquid drop at the tip of the needle.
Držite brizgo v eni roki tako, da bo igla usmerjena naravnost navzgor, kot je prikazano na sliki B. Položite palec na bat brizge in počasi potisnite navzdol, dokler ne zagledate kapljice tekočine na vrhu igle.
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Zaradi pomanjkanja študij kompatibilnosti zdravila Kineret ne smemo mešati z drugimi zdravili.
After your injection discard the wet gauze or tissue with your syringe and clean the surface with a fresh tissue.
Po injiciranju zavrzite mokro gazo ali robček skupaj z brizgo in očistite površino s svežim robčkom.
Similar rates were obtained for the groups on the SOC level, except for eye disorders with 55 AEs (rate 0.5), whereof 35 ocular hyperemia (which could also be a symptom of CAPS) in the CIAS1 group, and 4 AEs in the non-CIAS1 group (rate 0.1).
Podobne stopnje so bile dobljene za skupine na ravni organskih sistemov, razen za očesne bolezni s 55 neželenimi dogodki (stopnja 0,5), od tega 35 očesnih hiperemij (kar je lahko tudi simptom CAPS) v skupini CIAS1 in 4 neželeni dogodki v skupini ne-CIAS1 (stopnja 0,1).
Allow the pre-filled syringe to reach room temperature before injecting.
Napolnjena brizga naj pred injiciranjem doseže sobno temperaturo.
Side effects with frequency not known (frequency cannot be estimated from the available data): - Signs of liver disorders such as yellow skin and eyes, nausea, loss of appetite, dark-coloured urine and light-coloured stools.
Neželeni učinki z neznano pogostnostjo (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov): - znaki jetrnih bolezni, kot so rumena koža in oči, slabost izguba teka, temno obarvani urin in svetlo obarvano blato.
For the purpose of ambulatory use, Kineret may be removed from the refrigerator for 12 hours at temperature not above 25 °C, without exceeding the expiry date.
V primerih ambulantne uporabe se sme zdravilo Kineret hraniti izven hladilnika 12 ur pri temperaturi do 25 °C, če pri tem ni prekoračen datum roka uporabnosti zdravila.
Decreased acute phase protein levels are noted within the first weeks of treatment.
V prvih tednih zdravljenja so opazili znižane ravni beljakovin akutne faze.
Analysis of treatment-emergent AEs classified by presence of CIAS1 mutation showed that there were no major differences between the CIAS1 and non-CIAS1 groups in overall AE reporting rates, 7.4 and 9.2, respectively.
Analiza neželenih učinkov, ki se pojavljajo ob zdravljenju, razvrščenih glede na prisotnost mutacij CIAS1, je pokazala, da v celotnih poročanih stopnjah neželenih učinkov ni bilo bistvenih razlik med skupinami CIAS1 in ne-CIAS1, in sicer 7,4 oziroma 9,2.
However, any of the following symptoms may indicate an allergic reaction to Kineret, so you should seek immediate medical attention.
Pojav katerega od naštetih simptomov lahko kaže na alergijsko reakcijo na zdravilo Kineret, zato nemudoma poiščite zdravniško pomoč.
If you feel unwell in any way you should contact your doctor or nurse immediately.
Če se kakor koli slabo počutite, nemudoma stopite v stik s svojim zdravnikom ali medicinsko sestro.
Also persistent low-grade fever, weight loss, and persistent cough can be signs of an infection.
Tudi vztrajna rahlo zvišana telesna temperatura, izguba telesne mase in vztrajni kašelj so lahko znaki okužbe.
Combined anakinra and methotrexate treatment demonstrates a statistically and clinically significant reduction in the severity of the signs and symptoms of RA in patients who have had an inadequate response to methotrexate alone (38% vs. 22% responders as measured by ACR20 criteria).
Kombinirano zdravljenje z anakinro in metotreksatom je pokazalo statistično in klinično pomembno zmanjšanje resnosti znakov in simptomov RA pri bolnikih, pri katerih je bil odziv na metotreksat sam nezadosten (38 % proti 22 % bolnikov, ki so se odzvali po kriterijih ACR20).
In CAPS patients approximate dose linearity with a slight tendency to higher than proportional increase has been noted.
CAPS so opazili približno premosorazmernost z odmerkom z rahlo nagnjenostjo k več kot sorazmernemu povečanju.
How do you or the person injecting you, use the Kineret pre-filled syringe?
Kako naj vi sami ali oseba, ki vam injicira zdravilo, uporabite napolnjeno injekcijsko brizgo zdravila Kineret?
Alternating the injection site is recommended to avoid discomfort at the site of injection.
Priporočljivo je menjavati mesto injiciranja, da se izognemo težavam na mestu injiciranja.
Neither did anakinra increase the incidence of chromosomal abnormalities or micronuclei in bone marrow cells in mice.
Prav tako anakinra ni zvečala incidence kromosomskih nenormalnosti ali mikrojeder v celicah kostnega mozga pri miših.
16 patients completed the subsequent open label phase and among 7 responders at month 12, 6 had stopped glucocorticoid treatment and 5 of them had inactive disease.
16 bolnikov je zaključilo poznejšo odprto fazo in med 7 bolniki z odzivom v 12. mesecu jih je 6 prenehalo z zdravljenjem z glukokortikoidi, 5 pa jih je imelo neaktivno bolezen.
In addition to the evaluation of clinical symptoms and inflammatory markers in severe CAPS, assessments of inflammation of the CNS, including the inner ear (MRI or CT, lumbar puncture, and audiology) and eyes (ophthalmological assessments) are recommended after an initial 3 months of treatment, and thereafter every 6 months, until effective treatment doses have been identified.
Poleg ovrednotenja kliničnih simptomov in označevalcev vnetja pri težkih oblikah CAPS, se priporoča tudi ocenjevanje vnetja centralnega živčnega sistema (CŽS), vključno z notranjim ušesom (MRI ali CT, lumbalna punkcija in preiskava sluha) in očmi (oftalmološki pregled) po 3 mesecih začetnega zdravljenja in pozneje vsakih 6 mesecev, dokler niso ugotovljeni učinkoviti zdravilni odmerki.
• The used pre-filled syringe and any gauze or tissue with Kineret solution should be disposed of in accordance with local requirements.
• Uporabljeno napolnjeno injekcijsko brizgo in gazo ali robček z raztopino zdravila Kineret zavrzite v skladu z lokalnimi predpisi.
The safety profile in paediatric patients was similar to that seen in adult populations and no clinically relevant new adverse reactions were seen.
Varnostni profil pediatričnih bolnikov je bil podoben kot pri odrasli populaciji klinično pomembnih novih neželenih učinkov niso opazili.
Clinical efficacy and safety in CAPS
Klinična učinkovitost in varnost pri CAPS
Still's disease, in addition to various degrees of arthritis, is characterised by systemic inflammatory features such as spiking fever, skin rash, hepatosplenomegaly, serositis, and increased acute phase reactants driven by IL-1 activity.
Za Stillovo bolezen so poleg različnih stopenj artritisa značilni sistemski vnetni znaki, kot so zvišana telesna temperatura, kožni izpuščaj, hepatosplenomegalija, serozitis in povečani reaktanti akutne faze, ki jih povzroča aktivnost IL-1.
Kineret treatment should not be initiated in patients with active infections.
Zdravljenja z zdravilom Kineret se ne sme uvajati pri bolnikih z aktivnimi okužbami.
• How to manage injection site reactions
• kako obvladovati reakcije na mestu injiciranja.
Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs).
Zdravilo Kineret se lahko daje v obliki monoterapije ali v kombinaciji z drugimi protivnetnimi zdravili in protirevmatskimi zdravili, ki modificirajo potek bolezni (DMARD- disease-modifying antirheumatic drugs).
The European Medicines Agency has waived the obligation to submit the results of studies with Kineret in one or more subsets of the paediatric population in CAPS and RA (JIA) (see section 4.2 for information on paediatric use).
Kineret za eno ali več podskupin pediatrične populacije s CAPS in RA (JIA) (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Talk to your doctor before using Kineret: - if you have a history of recurring infections, or if you suffer from asthma.
Pred začetkom uporabe zdravila Kineret se posvetujte z zdravnikom ali farmacevtom: - če imate anamnezo ponavljajočih se okužb ali če imate astmo.
Kineret treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of RA, CAPS and Still's disease, respectively.
Zdravljenje z zdravilom Kineret morajo uvesti in nadzorovati zdravniki specialisti, ki so izkušeni v diagnostiki in zdravljenju RA, CAPS oziroma Stillove bolezni.
If any of the following happen, tell your doctor immediately:
Nemudoma obvestite zdravnika, če se zgodi kaj od naslednjega:
Other medicines and Kineret
Druga zdravila in zdravilo Kineret
The safety and efficacy have been demonstrated in a published randomized controlled study in 24 SJIA patients treated with Kineret for up to 1 year.
Varnost in učinkovitost sta bili dokazani v objavljeni randomizirani nadzorovani študiji pri 24 bolnikih s SJIA, ki so se z zdravilom Kineret zdravili do 1 leta.
In subjects with RA, maximum plasma concentrations of anakinra occurred at 3 to 7 hours after subcutaneous administration of anakinra at clinically relevant doses (1 to 2 mg/kg; n = 18).
Pri osebah z RA so se največje koncentracije anakinre v plazmi pojavile 3 do 7 ur po subkutani aplikaciji anakinre v klinično primernih odmerkih (1 do 2 mg/kg; n = 18).
No patient withdrew from Kineret treatment due to adverse reactions.
Noben bolnik ni odstopil od zdravljenja z zdravilom Kineret zaradi neželenih učinkov.
The safety and efficacy of anakinra in combination with methotrexate have been demonstrated in 1,790 RA patients ≥ 18 years of age with varying degrees of disease severity.
Varnost in učinkovitost anakinre v kombinaciji z metotreksatom so dokazali pri 1790 bolnikih z RA, starih ≥ 18 let z različnimi stopnjami izraženosti bolezni.
Kineret has been studied in 36 CAPS patients, 15 SJIA patients and 71 patients with other forms of JIA, aged 8 months to <18 years, for up to 5 years.
Zdravilo Kineret so do 5 let proučevali pri 36 bolnikih s CAPS, 15 bolnikih s SJIA in 71 bolnikih z drugimi oblikami JIA, starih od 8 mesecev do < 18 let.
No dose adjustment are expected to be required.
Po pričakovanjih prilagajanje odmerka ne bo potrebno.
Pull straight as shown in Figure A. Do not touch the needle or push the plunger.
Potegnite ga naravnost dol, kot prikazuje slika A. Ne dotikajte se igle in ne pritiskajte na bat.
The thrombocytopenias have been mild, i.e. platelet counts have been > 75 x109/l.
Trombocitopenija je bila blaga, tj. število trombocitov je bilo > 75 x 109/l.
The solution should not be used if it is discoloured or cloudy, or if any particles other than translucent-to-white particles are present.
Raztopine ne smete uporabiti, če je obarvana ali motna, ali če vsebuje kakšne druge delce razen prosojnih do belih.
Anakinra inhibits responses elicited by IL-1 in vitro, including the induction of nitric oxide and prostaglandin E2 and/or collagenase production by synovial cells, fibroblasts, and chondrocytes.
Anakinra zavira odzive, ki jih izzove IL-1 in vitro, med drugim indukcijo tvorbe dušikovega oksida in prostaglandina E2 in/ali kolagenaze v sinovialnih celicah, fibroblastih in hondrocitih.
In addition, in a clinical trial 6% of 86 paediatric patients with JIA, whereof none of the 15 SJIA subtype patients, tested seropositive at least once during the study for neutralizing anti-anakinra antibodies.
Poleg tega je bilo v enem kliničnem preskušanju 6 % od 86 pediatričnih bolnikov z JIA, pri čemer nobeden ni bil med 15 bolniki s podtipom SJIA, vsaj enkrat med študijo seropozitivnih pri testiranju za nevtralizirajoča protitelesa proti anakinri.
• If your doctor has prescribed a 100 mg dose you should continue to the “How to prepare a
• Če vam je zdravnik predpisal odmerek 100 mg, preberite poglavje „Kako pripraviti odmerek
- The active substance is anakinra.
- Učinkovina je anakinra.
Kineret is eliminated by glomerular filtration and subsequent tubular metabolism.
Zdravilo Kineret se izloča z glomerularno filtracijo in nadaljnjo tubularno presnovo.
The active substance of Kineret is anakinra, this works in the same way as your natural interleukin-1 blocking protein.
Učinkovina v zdravilu Kineret je anakinra, ki deluje na enak način kot vaša naravna beljakovina, ki blokira interlevkin-1.
In clinical trials in RA, up to 3% of adult patients tested seropositive at least once during the study for neutralizing anti-anakinra antibodies.
V kliničnih preskušanjih RA je bilo do 3 % odraslih bolnikov vsaj enkrat med študijo seropozitivnih za nevtralizirajoča protitelesa proti anakinri.
Your doctor will have to decide if you can still be given Kineret; - if you have a history of increased levels of liver enzymes; - if you require vaccinations.
Vaš zdravnik bo moral odločiti, ali lahko kljub temu dobite zdravilo Kineret; - če imate v anamnezi zvišane vrednosti jetrnih encimov;
It is not known whether anakinra is excreted in human milk.
Ni znano, ali se anakinra izloča v materino mleko.
The activated inflammasome results in proteolytic maturation and secretion of IL-1β, which has a broad range of effects including systemic inflammation.
Aktivirani inflamasom povzroči proteolitično dozorevanje in izločanje IL-1β, ki ima širok spekter učinkov, vključno s sistemskim vnetjem.